- Home
- HMST vs INZY Comparison
HMST vs INZY Comparison
Compare HMST & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- INZY
- Stock Information
- Founded
- HMST 1921
- INZY 2015
- Country
- HMST United States
- INZY United States
- Employees
- HMST 819
- INZY N/A
- Industry
- HMST Major Banks
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- INZY Health Care
- Exchange
- HMST Nasdaq
- INZY Nasdaq
- Market Cap
- HMST 194.6M
- INZY 188.2M
- IPO Year
- HMST 2012
- INZY 2020
- Fundamental
- Price
- HMST $10.32
- INZY $1.36
- Analyst Decision
- HMST Buy
- INZY Strong Buy
- Analyst Count
- HMST 2
- INZY 8
- Target Price
- HMST $14.75
- INZY $17.75
- AVG Volume (30 Days)
- HMST 176.5K
- INZY 1.0M
- Earning Date
- HMST 01-27-2025
- INZY 03-11-2025
- Dividend Yield
- HMST N/A
- INZY N/A
- EPS Growth
- HMST N/A
- INZY N/A
- EPS
- HMST N/A
- INZY N/A
- Revenue
- HMST $75,702,000.00
- INZY N/A
- Revenue This Year
- HMST N/A
- INZY N/A
- Revenue Next Year
- HMST $9.32
- INZY N/A
- P/E Ratio
- HMST N/A
- INZY N/A
- Revenue Growth
- HMST N/A
- INZY N/A
- 52 Week Low
- HMST $8.09
- INZY $1.24
- 52 Week High
- HMST $16.10
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- HMST 47.32
- INZY 29.28
- Support Level
- HMST $9.61
- INZY $1.35
- Resistance Level
- HMST $10.58
- INZY $1.62
- Average True Range (ATR)
- HMST 0.56
- INZY 0.13
- MACD
- HMST 0.02
- INZY 0.04
- Stochastic Oscillator
- HMST 53.42
- INZY 32.89
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.